CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MagnaPharm aims to control the polymorphism of pharmaceutical compounds by utilizing high magnetic fields during crystallization. This technique could revolutionize drug development by enabling the production of desired crystal forms for various medications.
This H2020-FETOPEN-2016-2017 proposal initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields.
The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds, and hence on society.It is proposed that MagnaPharm will drive forward innovation in pharmaceuticals by exploiting our new discovery that the polymorph and properties of carbamazepine, indomethacin and coronene can…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
STICHTING RADBOUD UNIVERSITEIT
Netherlands, Nijmegen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Ireland, Limerick
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
